News

Filter

Current filters:

Hyperion Therapeutics

Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm

24-04-2014

US biotech firm Hyperion Therapeutics has entered into a definitive agreement to acquire Andromeda Biotech,…

Andromeda BiotechBiotechnologyDiabetesDiaPep277Hyperion TherapeuticsMergers & Acquisitions

SOBI gains rights to distribute Ravicti in Middle East

01-10-2013

Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris

04-02-2013

The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

Hyperion gets rights to Ravicti, and perhaps more, from Ucyclyd

25-03-2012

Privately-held US firm Hyperion Therapeutics has acquired worldwide rights to the investigational drug…

AmmonulBuphenylGastro-intestinalsHyperion TherapeuticsLicensingMedicis PharmaceuticalNephrology and HepatologyPharmaceuticalRavictiUcyclyd Pharma

COMPANY SPOTLIGHT

Menarini

Back to top